ALUME BIOSCIENCES SECURES $13 M IN SERIES B FINANCING

/PRNewswire/ -- Alume Biosciences, Inc. has secured $13 million in Series B financing to advance its lead candidate, Bevonescein (ALM-488), in Phase 3 clinical...

Related Keywords

San Diego ,California ,United States ,Alume Biosciences ,Magda Marquet ,Prnewswire Alume Biosciences Inc , ,Johnson Innovation ,